Gladman DD, Charles-Schoeman C, McInnes IB, et al. - Since tofacitinib [an oral Janus kinase inhibitor that treats psoriatic arthritis (PsA)] causes an elevation in circulating lipid levels in some patients, researchers examined cardiovascular disease risk factors as well as major adverse cardiovascular events (MACE) in patients managed by tofacitinib 5 or 10 mg twice daily plus conventional synthetic disease-modifying antirheumatic drugs for active PsA. They pooled data from 2 phase III studies and 1 ongoing long-term extension. This study involved 783 tofacitinib-treated patients. Findings revealed increases in serum lipid level at month 3 after tofacitinib treatment in PsA; such increases were found to be consistent with observations in rheumatoid arthritis and psoriasis. They also noted low incidence rate of hypertension-associated adverse events and MACE; long-term follow-up is ongoing.